Scarica l'app Stockscreener
24.62
0.51%
0.1012
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
What to expect from Intellia Therapeutics Inc. in the next 30 daysJuly 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
Is Intellia Therapeutics Inc. showing signs of accumulationJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
Risk adjusted return profile for Intellia Therapeutics Inc. analyzed2025 Risk Factors & Expert Approved Trade Ideas - newser.com
What Recent Gene Editing Breakthroughs Mean for the Future of Intellia Therapeutics Stock - Yahoo Finance
Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment - Yahoo Finance
A Look at Intellia Therapeutics’s Valuation Following Breakthrough ATTR Data and HAELO Study Milestone - Yahoo Finance
Published on: 2025-10-12 05:21:21 - newser.com
Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Will Intellia Therapeutics Inc. (38I) stock profit from automation wave2025 Fundamental Recap & AI Driven Stock Reports - newser.com
Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6% - MSN
CRISPR Market Size, Share, Recent Developments, Growth - openPR.com
Using flow based indicators on Intellia Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Intellia Therapeutics Hits Day High with 19.72% Surge in Stock Price - Markets Mojo
Intellia Therapeutics Hits Day High with 10.71% Surge in Stock Price - Markets Mojo
Intellia Therapeutics Hits New 52-Week High at $26.45 - Markets Mojo
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside - ts2.tech
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance
Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Can Intellia Therapeutics Inc. (38I) stock test all time highsM&A Rumor & Safe Entry Point Identification - newser.com
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - sharewise.com
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook - ts2.tech
Is Intellia Therapeutics Inc 38I a good long term investmentRetail Investor Activity & Actionable Entry & Exit Points Daily - earlytimes.in
Intellia Therapeutics (NASDAQ:NTLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Intellia Therapeutics (NTLA) Surges Over 23% in Market Trading - GuruFocus
On Course: Intellia CSO Offers Clinical Update of In Vivo Gene Editing Therapies at ESGCT - Genetic Engineering and Biotechnology News
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - AOL.com
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - sharewise.com
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Supercharged Gene-Editing: Intellia’s 63% Rally Just The Start, Say Analysts - NAI500
Intellia Therapeutics Inc Stock Analysis and ForecastBear Market Strategies & Easy Tools to Analyze Your Investment Risk - earlytimes.in
1 Stock Up by 63% This Year That Could Double, According to Wall Street - Yahoo Finance
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com - Investing.com Canada
Intellia Therapeutics (NTLA) Sees Stock Rise Following Analyst U - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Upgraded by JMP Securities to Market Outperform Rating - MarketBeat
JMP Securities Upgrades Intellia Therapeutics (NTLA) - Nasdaq
What Analysts Are Saying About Intellia Therapeutics Stock - Benzinga
Intellia Therapeutics (NTLA) Upgraded by JMP Securities to Marke - GuruFocus
Published on: 2025-10-06 06:23:31 - newser.com
Intellia Therapeutics (NTLA) Sees Strong Gains as Ark Invest Inc - GuruFocus
Cathie Wood's Ark Invest weekly recap: adds more Alibaba, Baidu, Kodiak AI, Intellia to its funds (ARKK:BATS) - Seeking Alpha
How Intellia Therapeutics Inc. (38I) stock performs in easing cyclesQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Citizens upgrades Intellia Therapeutics stock rating on strong HAE outlook - Investing.com
How Intellia Therapeutics Inc. stock reacts to global recession fearsQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details - MSN
Intellia Therapeutics shares up after Wolfe upgrade - MSN
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought - AOL.com
Intellia Therapeutics (NTLA) Is Up 22.4% After Promising Phase 1 Data and ARK Investment Buy-In—What's Changed - Sahm
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Executive Makes Notable Stock Sale - TipRanks
Intellia Therapeutics (NASDAQ:NTLA) CAO Sells $32,517.98 in Stock - MarketBeat
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener
65,200 RSUs: Intellia Grants Equity to Six New Hires, Vesting Over Three Years - Stock Titan
Is Intellia Therapeutics Inc. (38I) stock supported by strong fundamentals2025 Performance Recap & AI Powered Buy and Sell Recommendations - newser.com
Intellia Therapeutics (NTLA): Revisiting Valuation After Positive Clinical Advances and Pipeline Milestones - Sahm
Published on: 2025-10-03 05:23:01 - newser.com
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):